Jones BE, Ying J, Stevens V, et al. - This study was attempted to compare 30-day mortality among individuals hospitalized for pneumonia receiving empirical anti-MRSA therapy vs standard empirical antibiotic regimens. Between January 1, 2008, and December 31, 2013, Experts performed a retrospective multicenter cohort study of all hospitalizations in which individuals received either anti-MRSA or standard therapy for community-onset pneumonia in the Veterans Health Administration health care system. A total of 88,605 hospitalized individuals (86 851 men; median age, 70 years [interquartile range, 62-81 years]) were included. This research implies that empirical anti-MRSA therapy was not correlated with decreased mortality for any group of individuals hospitalized for pneumonia. These outcomes provide a growing body of evidence that questions the value of empirical use of anti-MRSA therapy using existing risk approaches.